Skip to main content

ESTRO consensus recommendations for high dose rate interstitial liver brachytherapy

In brief

Experts standardize how centers deliver liver brachytherapy for selected tumors

An expert panel offers standardized guidance for image-guided catheter placement, implantation techniques, treatment planning, and follow-up for selected liver tumors unsuitable for surgery. The recommendations also review outcomes, toxicities, and adverse-event management, aiming to support safer, more consistent care and comparable research; they are consensus guidance, not evidence from a new clinical trial.

Journal
Clinical and translational radiation oncology (Q1)
Published
1 November 2026
Study design
Practice guideline / consensus
Evidence level
Level 1, High (CEBM 1c)
Authors
Stefanie Corradini, Maya Rottler, Mateusz Bilski, Peter Hass, Kathrin Hering, Efstratios Karagiannis, et al.
PMID
43036317
DOI
10.1016/j.ctro.2026.101343

Why clinicians should know about it

Abstract

High dose rate (HDR) interstitial liver brachytherapy has become one of the established local ablative treatment options for selected primary and secondary liver tumours that are unsuitable for surgical resection. With its steep dose gradient and high conformality, it enables precise dose delivery to the target while effectively sparing surrounding healthy liver tissue and adjacent organs at risk. These consensus recommendations provide comprehensive, standardised guidance on the technique and workflow of interstitial HDR liver brachytherapy, including image-guided catheter implantation, implantation techniques, and treatment planning. The recommendations further summarise available evidence on oncological outcomes, toxicities and adverse event management, and outline principles for post-treatment follow-up. The consensus recommendations were developed by an expert panel of the GEC-ESTRO Gastrointestinal Working Group based on published evidence and collective clinical experience. They aim to harmonise practice across centres, promote safe and effective treatment delivery, and facilitate future research and data comparison in this evolving field of liver-directed radiotherapy.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.